bevacizumab gamma (Lytenava®)
Application Details
HSE100056
25043
bevacizumab gamma
Lytenava®
Outlook Therapeutics
03/07/2025
27/05/2024
Application Status
Application Withdrawn at the Request of Applicant
25/06/2026
Proposed HSE Decision Issued to Applicant
05/06/2026
Reviewed by HSE Senior Leadership Team
02/06/2026
Reviewed by HSE Drugs Group
12/05/2026
HSE Drugs Group Review Pending
24/02/2026
Proposal from Applicant Under Review
03/02/2026
Awaiting Proposal from Applicant
02/10/2025
Applicant Meeting Held with CPU
02/10/2025
Rapid Review Completed
30/07/2025
Rapid Review Commissioned
03/07/2025
Pricing and Reimbursement Application Complete
03/07/2025